Does anyone know anything further about the Argenica Therapeutics IPO (AGN) that is listing this Friday as it seems the drug they are developing will be a direct competitor to Nyrada’s TBI drug. Their website states they will be:
‘Developing novel therapeutics to reduce brain damage after stroke and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans. Our aim is for our therapeutics to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.
Listening to the CEO’s Small Caps interview recently, it sounded very similar to the drug Nyrada is developing and just interested as to whether we thought this was of any concern?
NYR Price at posting:
33.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)